Ernexa Therapeutics Inc.
General ticker "ERNA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $139.3M (TTM average)
Ernexa Therapeutics Inc. does not follow the US Stock Market performance with the rate: -27.2%.
Estimated limits based on current volatility of 4.6%: low 0.20$, high 0.22$
Factors to consider:
- Total employees count: 9 as of 2022
- Current price 68.2% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.67$, 2.60$]
- 2026-12-31 to 2027-12-31 estimated range: [0.63$, 2.38$]
Short-term ERNA quotes
Long-term ERNA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.07MM | $0.58MM | $0.00MM |
| Operating Expenses | $21.20MM | $16.26MM | $9.32MM |
| Operating Income | $-21.14MM | $-15.67MM | $-9.32MM |
| Non-Operating Income | $-0.54MM | $-28.84MM | $-4.81MM |
| Interest Expense | $0.61MM | $6.75MM | $0.03MM |
| R&D Expense | $5.92MM | $4.60MM | $4.16MM |
| Income(Loss) | $-21.67MM | $-44.51MM | $-14.13MM |
| Taxes | $-0.00MM | $0.03MM | $-0.04MM |
| Profit(Loss)* | $-21.67MM | $-44.54MM | $-14.10MM |
| Stockholders Equity | $2.23MM | $1.70MM | $2.40MM |
| Assets | $49.13MM | $5.27MM | $5.83MM |
| Operating Cash Flow | $-20.41MM | $-15.84MM | $-7.02MM |
| Capital expenditure | $0.02MM | $0.37MM | $0.04MM |
| Investing Cash Flow | $-0.02MM | $-0.36MM | $-0.04MM |
| Financing Cash Flow | $16.56MM | $6.26MM | $7.21MM |
| Earnings Per Share** | $-4.08 | $-1.57 | $-2.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.